pT3-EF1a-c-Met Citations (3)

Originally described in: Distinct pathways of genomic progression to benign and malignant tumors of the liver.
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6. Epub 2007 Sep 4. PubMed Journal

---

Articles Citing pT3-EF1a-c-Met

Articles
A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model. Wei Y, Wang Y, Liu N, Qi R, Xu Y, Li K, Feng Y, Shi B. Front Pharmacol. 2022 Jan 18;12:820446. doi: 10.3389/fphar.2021.820446. eCollection 2021. PubMed
Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET. Pal AS, Agredo A, Lanman NA, Son J, Sohal IS, Bains M, Li C, Clingerman J, Gates K, Kasinski AL. Cancer Res. 2022 Apr 15;82(8):1534-1547. doi: 10.1158/0008-5472.CAN-20-0821. PubMed
Lipocalin 2 Reduces MET Levels by Inhibiting MEK/ERK Signaling to Inhibit Nasopharyngeal Carcinoma Cell Migration. Li JP, Lin CW, Huang CC, Lu YT, Ho YT, Yang SF, Hsin CH. Cancers (Basel). 2022 Nov 21;14(22):5707. doi: 10.3390/cancers14225707. PubMed

If you have published an article using this material, please email us at to have your article added to this page.